Gsa Capital Partners LLP Crinetics Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 16, 2024	SELL	$25.62 - $37.07 $49,754 - $71,989	-1,942 Reduced 17.61%	9,083 $323,000
Q3 2023 Nov 15, 2023	SELL	$15.97 - $30.59 $385,883 - $739,146	-24,163 Reduced 68.67%	11,025 $327,000
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $90,180 - $135,298	5,733 Added 19.46%	35,188 $634,000
Q1 2023 May 12, 2023	BUY	$15.31 - $21.1 $450,956 - $621,500	29,455 New	29,455 $473,000
Q2 2022 Aug 09, 2022	SELL	$16.49 - $27.64 $245,651 - $411,753	-14,897 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$17.15 - $28.31 $43,938 - $72,530	2,562 Added 20.77%	14,897 $327,000
Q4 2021 Feb 14, 2022	SELL	$19.35 - $28.41 $80,205 - $117,759	-4,145 Reduced 25.15%	12,335 $350,000
Q3 2021 Nov 12, 2021	BUY	$16.88 - $25.23 $278,182 - $415,790	16,480 New	16,480 $347,000

244

78.2M

268K

197K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.73B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.